EQRx is a revolutionary brand that aims to make branded medicines more affordable without compromising on quality. As the cost of new medicines continues to rise, EQRx recognizes the need for a solution to ensure accessibility for health systems and patients. They are focused on developing novel, patent-protected treatments, starting with cancer and immune-inflammatory diseases, where the high price-tag has become a burden.

EQRx works closely with health systems to create a new model that brings down the price of new medicines, starting in Europe. Their extensive pipeline includes more than 10 therapeutic programs in various stages of clinical development. What sets EQRx apart is that they offer better-priced therapies before generics and biosimilars become available.

While generics and biosimilars offer more affordable options, they are often delayed due to patent expirations. EQRx's efficient business model allows them to develop products quickly, offering market availability ahead of their competitors. Their approach provides financial relief and expands treatment options for health systems and patients.

By introducing a new category of more sustainably-priced therapies, EQRx aims to change the trajectory of medicine pricing and make innovative treatments more attainable